

Douglas I Lin

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7231570/douglas-i-lin-publications-by-citations.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69 papers	901 citations	15 h-index	29 g-index
77 ext. papers	1,241 ext. citations	3.9 avg, IF	4.09 L-index

#	Paper	IF	Citations
69	Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. <i>Molecular Cell</i> , 2006 , 24, 355-66	17.6	291
68	Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. <i>Genes and Development</i> , 2007 , 21, 2908-22	12.6	100
67	Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 287-93	6.7	69
66	Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. <i>European Urology</i> , 2016 , 70, 516-21	10.2	61
65	Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. <i>European Urology</i> , 2018 , 73, 71-78	10.2	54
64	SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association. <i>Modern Pathology</i> , 2019 , 32, 1675-1687	9.8	38
63	A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. <i>Modern Pathology</i> , 2021 , 34, 252-263	9.8	25
62	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , 2021 , 12, 2487	17.4	24
61	Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type. <i>Gynecologic Oncology</i> , 2017 , 147, 626-633	4.9	23
60	Comparing histologic evaluation of prostate tissue using nonlinear microscopy and paraffin H&E: a pilot study. <i>Modern Pathology</i> , 2019 , 32, 1158-1167	9.8	19
59	Automated clear cell renal carcinoma grade classification with prognostic significance. <i>PLoS ONE</i> , 2019 , 14, e0222641	3.7	17
58	Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss. <i>Gynecologic Oncology</i> , 2020 , 157, 357-366	4.9	17
57	Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors. <i>Gynecologic Oncology</i> , 2018 , 151, 401-406	4.9	17
56	Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts. <i>Gynecologic Oncology</i> , 2020 , 157, 106-114	4.9	16
55	Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas. <i>PLoS ONE</i> , 2018 , 13, e0199688	3.7	16
54	Amplification of the pathway in pelvic high-grade serous carcinomas of tubo-ovarian and endometrial origin. <i>Molecular and Clinical Oncology</i> , 2017 , 7, 301-307	1.6	15
53	Targeted Screening With Combined Age- and Morphology-Based Criteria Enriches Detection of Lynch Syndrome in Endometrial Cancer. <i>International Journal of Surgical Pathology</i> , 2016 , 24, 297-305	1.2	12

52	Amplification of the bromodomain-containing protein 4 gene in ovarian high-grade serous carcinoma is associated with worse prognosis and survival. <i>Molecular and Clinical Oncology</i> , 2015 , 3, 1291-1294 ¹⁶ ¹¹		
51	Hepatocellular Adenoma of the Placenta With Updated Immunohistochemical and Molecular Markers: A Case Report. <i>International Journal of Surgical Pathology</i> , 2016 , 24, 640-3	1.2	8
50	Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	7
49	Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions. <i>BJU International</i> , 2020 , 125, 739-746	5.6	7
48	Improved survival associated with somatic mutations in copy-number low endometrioid endometrial adenocarcinoma. <i>Oncology Letters</i> , 2015 , 10, 2743-2748	2.6	6
47	TNS1-ALK Fusion in a Recurrent, Metastatic Uterine Mesenchymal Tumor Originally Diagnosed as Leiomyosarcoma. <i>Acta Medica Academica</i> , 2019 , 48, 116-120	0.8	5
46	Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. <i>Oncology</i> , 2020 , 98, 905-912	3.6	5
45	Molecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin. <i>Gynecologic Oncology Reports</i> , 2020 , 34, 100652	1.3	5
44	Clinicopathological and genomic characterization of BCORL1-driven high-grade endometrial stromal sarcomas. <i>Modern Pathology</i> , 2021 , 34, 2200-2210	9.8	4
43	Mixed Endometrioid Adenocarcinoma and Müllerian Adenosarcoma of the Uterus and Ovary: Clinicopathologic Characterization With Emphasis on its Distinction From Carcinosarcoma. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 374-383	6.7	3
42	Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary. <i>Modern Pathology</i> , 2021 , 34, 983-993	9.8	3
41	Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. <i>Modern Pathology</i> , 2021 , 34, 1425-1433	9.8	3
40	Immunotherapy predictive biomarkers in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1023-1023	2.2	2
39	Primary versus metastatic intrahepatic cholangiocarcinoma: A comparative comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 578-578	2.2	2
38	Endometrioid Tubal Intraepithelial Neoplasia (E-TIN) of the Fallopian Tube: A Case Series. <i>International Journal of Gynecological Pathology</i> , 2020 , 39, 552-557	3.2	2
37	Primary tumor (p-bx) versus metastatic tumor (m-bx) tissue versus liquid biopsy (lb) in intrahepatic cholangiocarcinoma (IHCC): A comparative comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4579-4579	2.2	1
36	Comprehensive genomic profiling (CGP) in post-systemic treatment (Post) metastatic sites (MET) and pretreatment (Pre) primary tumors (PT) of metastatic prostate cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 175-175	2.2	1
35	NF2 mutation-driven renal cell carcinomas (RCC): A comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 726-726	2.2	1

34	-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of \pm -Wild-Type Tumor With Frequent Genomic Alterations and 1p/19q-Codeletion. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	1
33	Clinical Implications of Genomic Loss of Heterozygosity in Endometrial Carcinoma. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	1
32	Clinically advanced penile (pSCC) and male urethral (uSCC) squamous cell carcinoma: A comparative genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2-2	2.2	1
31	Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors. <i>Gynecologic Oncology</i> , 2021 , 162, 728-734	4.9	1
30	Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12 139 Cancer Patients. <i>Clinical Chemistry</i> , 2021 , 67, 1554-1566	5.5	1
29	Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.. <i>JAMA Network Open</i> , 2022 , 5, e225394	10.4	1
28	Metastatic penile (mPSCC), uterine cervical (mCSCC), and skin (mSSCC) squamous cell carcinomas: A comparative genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4585-4585	2.2	0
27	Differential genomic landscape of clinically advanced/metastatic chordomas (mChor) based on primary tumor site.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11521-11521	2.2	0
26	PD-L1 expression, tumor mutational burden, and microsatellite instability status in 746 pancreas ductal adenocarcinomas.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 757-757	2.2	0
25	Comprehensive genomic profiling (CGP) of histologic subtypes of urethral carcinomas (UrthCa).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5087-5087	2.2	0
24	Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas. <i>Oncologist</i> , 2021 , 26, 375-382	5.7	0
23	Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: A comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3130-3130	2.2	0
22	A sporadic gastric-type endocervical adenocarcinoma with endometrial involvement and bilateral ovarian metastasis, a case report. <i>Gynecologic Oncology Reports</i> , 2020 , 32, 100572	1.3	
21	Comprehensive genomic profiling (CGP) of histologic subtypes of urethral carcinomas (UrthCa).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 426-426	2.2	
20	Metastatic renal cell carcinoma (mRCC) in young patients: A comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 727-727	2.2	
19	Extra-mammary Paget's disease (EMPD) of the skin: A comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9591-9591	2.2	
18	FGFR2: A pan-genomic target.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3099-3099	2.2	
17	Anal melanoma: A comparative comprehensive genomic profiling study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9566-9566	2.2	

16	Contrasting genomic profiles in post-systemic treatment metastatic sites (MET), pretreatment primary tumors (PT), and liquid biopsies (LB) of clinically advanced prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5534-5534	2.2
15	Acquired RB1 mutations in estrogen receptor-positive (ER+) clinically advanced and metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1053-1053	2.2
14	Increased tumor purity and improved biomarker detection using precision needle punch enrichment of pathology specimen paraffin blocks: Method validation and implementation in a prospective clinical trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3622-3622	2.2
13	Primary adult retroperitoneal sarcoma (RS): Comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11541-11541	2.2
12	Clinically aggressive malignancies associated with STK11 germline mutations (STK11GCa): A comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3558-3558	2.2
11	Genomic landscape of MSH6-mutated clinically advanced castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5062-5062	2.2
10	Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8555-8555	2.2
9	Assessment of predictive biomarker prevalence in molecularly defined adult-type ovarian granulosa cell tumors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5567-5567	2.2
8	HHV-8 positive clinically advanced castrate-resistant prostate cancer (mCRPC): A potentially distinct molecular subset.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 163-163	2.2
7	HPV-16 positive clinically advanced squamous cell carcinoma of the urinary bladder (mBSCC): A comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 481-481	2.2
6	Expanding the use of targeted therapy for urothelial bladder cancer (UBC): Non-FGFR3 receptor tyrosine kinase (RTK) gene rearrangements (ReAr) and fusions (fus).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 550-550	2.2
5	Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 156-156	2.2
4	Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus taxane chemotherapy benefit in metastatic castration-resistant prostate cancer: A real-world biomarker study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 162-162	2.2
3	Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 563-563	2.2
2	Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (MTAP) genomic loss.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 164-164 ²	2.2
1	Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with clear cell RCC (ccRCC): Impact of FLCN genomic alteration (GA) status.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 292-292	2.2